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Advances in understanding
interferon-mediated immune
responses to enteric viruses in
intestinal organoids
Lila S. Nolan 1,2 and Megan T. Baldridge 2,3*
1
Department of Pediatrics, Division of Newborn Medicine, Washington University School of
Medicine, St. Louis Children’s Hospital, St. Louis, MO, United States, 2 Edison Family Center for
Genome Sciences and Systems Biology, Washington University School of Medicine, St. Louis, MO,
United States, 3 Department of Medicine, Division of Infectious Diseases, Washington University
School of Medicine, St. Louis, MO, United States

Interferons (IFN) are antiviral cytokines with critical roles in regulating
pathogens at epithelial barriers, but their capacity to restrict human enteric
viruses has been incompletely characterized in part due to challenges in
cultivating some viruses in vitro, particularly human norovirus. Accordingly,
advancements in the development of antiviral therapies and vaccine strategies
for enteric viral infections have been similarly constrained. Currently emerging
is the use of human intestinal enteroids (HIEs) to investigate mechanisms of
human enteric viral pathogenesis. HIEs provide a unique opportunity to
investigate host-virus interactions using an in vitro system that recapitulates
the cellular complexity of the in vivo gastrointestinal epithelium. This approach
permits the exploration of intestinal epithelial cell interactions with enteric
viruses as well as the innate immune responses mediated by IFNs and IFNstimulated genes. Here, we describe recent ﬁndings related to the production,
signaling, and function of IFNs in the response to enteric viral infections, which
will ultimately help to reveal important aspects of pathogenesis and facilitate
the future development of therapeutics and vaccines.
KEYWORDS

enteric virus, interferon, interferon-stimulated genes, norovirus, astrovirus, rotavirus,
organoid, enteroid

Introduction
Despite the substantial progress made in reducing the global burden of diarrheal
illness, diarrhea remains a signiﬁcant public health challenge. Diarrhea is a leading cause
of global mortality and is the ﬁfth leading cause of death among children, with an
associated mortality of 70.6 deaths per 100,000 (1). As a result, global initiatives to
address the prevention of morbidities and mortality associated with diarrheal illness have
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enriched with critical growth factors including Wnt3a,
R-spondin, and Noggin (5–7). This approach produces 3D
enteroids with the basolateral membrane in contact with the
Matrigel and media and the apical membrane within the luminal
surface (7). These enteroids develop complex
microenvironments with differentiation of intestinal epithelial
cell (IEC) subtypes and the formation of villus-like structures
(8). Human intestinal enteroids (HIEs) can recapitulate the stem
cell lineage as well as the differentiated cell type heterogeneity,
including enterocytes, goblet cells, and enteroendocrine cells, of
the in vivo tissue of origin, permitting HIEs to be used in the
study of the intestinal cellular landscape (6). These
heterogeneous cell populations can recapitulate in vivo
intestinal tissues in vitro, providing a more faithful
experimental model than immortalized and transformed cells
(6, 8–10). Further, differentiation methods to enrich for speciﬁc
cell types, particularly tuft cells, Paneth cells, and microfold (M)
cells which are typically rare or absent in organoids, can allow
for further study of the role of these cell types in human biology
and disease (6, 11).
A longstanding challenge in using 3D models has been the
difﬁculty in accessing the apical surface for the study of epithelial
interactions with luminal factors such as pathogens or nutrients
(8, 12, 13). While microinjection into the organoid luminal space
has been used to overcome this limitation, it remains a laborintensive and technically challenging technique (12, 13). After
enzymatic dissociation, tissue- or iPSC-derived organoids can be
reseeded as two-dimensional (2D) Transwell monolayer
cultures, which facilitates exposure and access to the apical
epithelium. However, 2D cultures can only be used short-term,
whereas 3D organoids can be readily passaged and are better
suited for long-term use (8). A recent innovation has been a
reversed-polarity apical-out model, in which the enteroids
are suspended in media rather than embedded in BME and

focused on the young pediatric population (1). Several virus
families have been identiﬁed as major etiologies of viral
gastroenteritis, including norovirus, sapovirus (both singlestranded positive-sense RNA viruses in the Caliciviridae
family), rotavirus (double-stranded RNA virus in the
Reoviridae family), astrovirus (single-stranded RNA virus in
the Astroviridae family), and adenovirus (double-stranded
DNA virus in the Adenoviridae family) (2, 3). Despite the
long-standing recognition of these pathogens as important
drivers of pediatric illness, many aspects of their in vivo
activity, such as cellular tropism and innate immune
regulation, have remained obscure. Thus, there remains a need
for suitable experimental models that recapitulate the dynamic
and complex features of the viral interactions with human
intestinal epithelium. The emergence of ex vivo intestinal
epithelial cultures, or “mini-intestines,” have guided
investigations of host-enteric pathogen interactions. While
these “mini-intestines” were ﬁrst applied to model hostbacterial dynamics and interactions between the intestinal
epithelium and organisms such as Escherichia coli, Clostridium
difﬁcile, and Salmonella typhi, this model system has also been
utilized to reveal novel and interesting aspects of host-virus
interactions and features of replication and pathogenesis for
enteric viruses (4).
Ex vivo intestinal epithelial cultures are achieved by isolation
of intestinal crypts from surgically resected intestinal tissue,
which contains human stem cells, or from human embryonic
or inducible pluripotent stem cells (iPSCs) (Figure 1). Primary
cultures derived from isolated crypts or stem cells are classiﬁed
as enteroids (from the small intestine) or colonoids (from the
colon), whereas those from iPSCs are termed organoids (5). The
derived stem cells are embedded in a basement membrane-like
matrix (BME), such as Matrigel, and cultured as selfperpetuating three-dimensional (3D) cultures in media

FIGURE 1

Human intestinal enteroid (HIE) derivation and culture for host-pathogen and disease modeling. HIEs are derived from the intestinal crypts and
directly embedded into basement membrane-like matrix (BME) to generate epithelial enteroid cultures with differentiated cell types to model
host-virus interactions. Figure created with BioRender.com.
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expression of IFNL1, IFNL2, and IFNL3 (28). These
observations suggest HIEs as an important model to
investigate IFNs as a shared biological response to multiple
human enteric viruses, but also highlight that different viruses
stimulate distinct antiviral defenses and IFN signaling
mechanisms in the intestinal epithelium during infection.
Here, we will review what is known for IFN-mediated
immune responses to enteric viral infections using HIE
models. We will also highlight future research directions of
interest for IFN-associated immune responses in acute viral
gastroenteritis that may contribute to a greater understanding
of the pathogenesis and treatment of enteric viral infections.

have an outward-facing apical surface readily accessible
to experimental agents in the culture media (6–10, 14).
These apical-out models may serve to facilitate the study of
host-pathogen interactions within the intestinal epithelium.
The ability to expand and maintain these primary epithelial
cells in a near-native state as self-organizing organotypic
cultures has signiﬁcantly contributed to the exploration of
human enteric virus pathogenesis (6, 8, 9). Notably, HIEs have
proven useful in the investigation of the production, signaling,
and function of innate immune cytokines interferons (IFNs) in
response to human enteric viruses. One of the ﬁrst lines of
defense against viral infection is the host innate immune
response, with the outcome of infection deﬁned by the
interaction between the virus and these responses. IFNmediated signaling pathways are critical aspects of this innate
response and are particularly important for host antiviral
activity. IFNs are classiﬁed into three types (I, II, and III), and
the induction of canonical type I and III IFN signaling is key to
viral control and immune responses at the gut mucosal interface
(15–17). The distinct effects of IFNs in mediating viral control
and regulating IFN-stimulated genes (ISGs) have been
thoroughly detailed in the context of host infection and
immune response (15, 17–20). Brieﬂy, IFNs secreted from
virus-infected cells engage cognate IFN receptors on the
surface of neighboring cells for the activation of Janus kinases
(JAK) and phosphorylation of transcription factors STAT1 and
STAT2, enabling the transcription of ISGs, which encode
effectors of the antiviral response and antagonize virus
replication (15, 20). In the context of enteric viral infections, a
current paradigm is that type I IFNs are produced from and act
to regulate viral infection of immune cells, thereby limiting
systemic dissemination from the intestine, but may also be
derived from and act on IECs in some contexts. In contrast,
type III IFNs are predominantly produced from and act more
speciﬁcally on IECs to limit local viral replication within the
intestine, secondary to more limited expression of the type III
IFN receptor (15, 20). While mouse models have implicated
IFNs as critical for the regulation of murine enteric viruses such
as murine norovirus, murine rotavirus, and murine astrovirus,
the roles of IFNs in the regulation of human enteric viruses have
been less carefully explored (21–27). A recent comparison of
RNA-sequencing datasets identiﬁed shared transcriptional
changes involving the innate immune response upon infection
of HIEs with multiple human enteric viruses, including genes
associated with Toll-like receptors, IFN receptors (IFNAR,
IFNGR, IFNLR), IFN-stimulated genes, and IFN-associated
chemokines (28). Virus-speciﬁc transcriptional changes were
also observed. For example, IFNE was detectable in the
datasets generated from astrovirus-infected duodenal HIEs and
norovirus-infected ileal HIEs, whereas a type III IFN response
was detected in response to rotavirus, with differential
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Human norovirus
Although human noroviruses (HNoVs) are the leading cause
of viral gastroenteritis worldwide, there are no approved
vaccines or antiviral drugs available to counter this pathogen.
NoVs are single-stranded positive-sense RNA viruses in the
Caliciviridae family. The NoV genus is classiﬁed into ten
genogroups, GI through GX, which are further divided into 49
capsid genotypes (29). Of these, human infections are primarily
induced by GI and GII viruses, whereas genogroup GV includes
murine NoV strains that naturally infect mice (30, 31).
Phenotype and severity of infection vary by individual strain,
with genotype GII.4 responsible for the majority of HNoV
infections (30, 31). A thorough understanding of both the
HNoV life cycle and how viral replication is affected by host
restrictions are needed but have been limited due to the lack of a
reproducible and robust in vitro cultivation system (10).

HNoV cultivation and IFN responses
in HIEs
Recent efforts have resulted in two HNoV culture systems,
the ﬁrst using immortalized B cells and the second using patientderived HIEs (32–34). The prior lack of a robust in vitro culture
system for HNoV was largely driven by limited knowledge of the
cell types that are permissive to HNoV replication (35).
Cultivation of a single strain of HNoV in B cells in one study
required the use of unﬁltered inoculum and commensal bacteria
as cofactors for replication (32, 33). However, HNoV can also
infect patients deﬁcient in B cells, implicating other cell types as
permissive for HNoV replication (36). Analysis of intestinal
biopsy samples from immunocompromised patients infected
with HNoV revealed the presence of HNoV major capsid
protein (VP1) and non-structural proteins (RdRp and VPg) in
a variety of intestinal cells, predominantly epithelial enterocytes,
thereby suggesting IECs as another likely permissive cell type for
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ISGs CXCL10 and IFI44L (43–45). Together, these results
suggest that IFN-JAK-STAT signaling pathways are strongly
activated in the transcriptomic response to HNoV infection (41).

HNoV replication (35). A recent report similarly identiﬁed
negative-sense viral RNA, a marker for active viral replication,
in enteroendocrine cells of immunocompromised pediatric
patients with HNoV gastroenteritis (37).
The capacity for HIEs to support HNoV replication in IECs,
speciﬁcally enterocytes, was subsequently conﬁrmed for both GI
and GII strains (34), and HIEs have since been used to evaluate
virus inactivation methods (38), neutralizing capacity of human
monoclonal antibodies (39), and levels of serum neutralizing
antibodies (40) among other applications. However, this system
has exhibited a variable capacity to permit replication of viral
strains. To address this issue, different components of the
intestinal milieu have been assessed, and improvements, such
as streamlined use of media containing bile, have been identiﬁed
to enhance replication of various HNoV strains (10).

IFN regulation of HNoV in HIEs
The effects of IFN signaling and exogenous IFN treatment
on HNoV infection have been recently explored using HIEs and
primary human B cells. Treatment of primary splenic B cells
with IFN-b signiﬁcantly reduces replication of HNoV genotype
GII.4 or GII.6 whereas pretreatment of B cells with neutralizing
antibodies against IFNs including IFN-a, IFN-b, and IFN-b2
enhances HNoV infection (46). Additionally, in HIEs, enhanced
replication of HNoV strains GII.3 and GII.4 occurs following
treatment with ruxolitinib, a JAK1/JAK2 inhibitor that blocks
type I and III IFN signaling (41). Similar effects are shown
following lentivirus-mediated expression of viral innate immune
antagonists bovine viral diarrhea virus protein and parainﬂuenza
virus type 5 protein to create organoid lines in which IFN
production is suppressed (41). GII.3 replication is also
signiﬁcantly enhanced in STAT1-/- HIEs, which lack all IFN
signaling, though intriguingly, GII.4 replication is not
(Figure 2A) (44). Additionally, treatment with exogenous type
I or III IFNs reduces replication of both GII.4 and GII.3 virus
strains in HIEs (Figure 2A) (41, 44). These studies are broadly
concordant with ﬁndings in the murine norovirus model,
wherein both endogenous type I and III IFN signaling have
been shown to limit infection (24, 47, 48), and for which type III

Building on these prior studies, to identify pathways that
may restrict HNoV replication in HIEs, roles for IFNs in
controlling viral replication, at times by strain-speciﬁc
mechanisms, have been investigated (41). Transcription factor
enrichment analysis of HNoV GII.4-infected HIEs identiﬁed
STAT1 and STAT2 binding sites as highly enriched in the
promoter regions of genes whose levels of expression were
signiﬁcantly upregulated following infection (41). Similarly,
HNoV GII.4 infection of HIEs stimulates a robust innate
response involving predominately a type III IFN response and
the induction of ISGs including ISG15 and ISG45 (28, 42).
Targeted proﬁling of immunological genes associated with
HNoV replication in HIEs suggests that the two most
upregulated immune-related genes with viral replication are

FIGURE 2

Human intestinal enteroids (HIEs) support the discovery of interferon (IFN) responses to enteric viruses. (A) STAT1-/- HIEs, which lack IFN
signaling, demonstrate enhanced norovirus GII.3 replication whereas exogenous type I and III IFN reduce replication of both GII.4 and GII.3 in
wild-type HIEs. (B) Human rotavirus (HRV) infection of HIEs induces type III IFNs, while pretreatment of HIEs with exogenous but not
endogenous type I and III IFNs can inhibit HRV replication. (C) Treatment with exogenous type I and III IFNs prior to human astrovirus (HAstV)
infection reduces viral replication while treatment with ruxolitinib, a JAK1/JAK2 inhibitor, increases HAstV replication. HAstV induces both type I
and III IFN responses. (D) Type I or III IFN treatment of HIE monolayers inhibits replication of adenovirus HAdV-41p. Figure created with
BioRender.com.
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HRV infection provides an opportunity to investigate host
immune responses and antiviral defenses in the effort to
address the unmet need to create effective therapeutics.

IFN is a potent in vivo antiviral (23, 24). Overall, there is an
important role for IFNs in regulating HNoV replication in HIEs
and their potential use as therapeutics against HNoV remains an
open possibility. Further investigation is required to better
elucidate the mechanisms by which speciﬁc antiviral ISGs
limit HNoV replication.

RV induces and is sensitive to IFN
signaling in HIEs

Human rotavirus and reovirus

Active RV infection occurs in host small intestinal
enterocytes and enterochromafﬁn cells and depends upon the
antagonism of type I and III IFNs and NF-kB signaling by viral
proteins including NSP1 (55–60). Importantly, RV strains differ
in their ability to antagonize IFN immune responses depending
upon their host species of origin. Homologous murine (EW-RV
strain) and heterologous (non-murine) simian (RRV)
rotaviruses can both induce similar type I IFN levels and ISGs
in the murine small intestine (61). However, EW-RV replication
is unaffected by the presence of IFNs, as detected by nearly
identical viral fecal shedding of EW-RV in mice lacking
receptors for either or both type I or III IFN (61). In contrast,
RRV replicates to signiﬁcantly higher titers in mice lacking
either or both type I or type III IFN receptors (61). These
ﬁndings are concordant with other studies that show that RV
infection induces activation of type I and III IFNs and antiviral
responses are greatly diminished when receptors for both IFN
types are lacking in murine models (26, 27, 61). Murine RVinfected murine IECs exhibit enhanced type III IFN expression
and predominantly type III IFN-dependent ISG expression,
supporting that type III IFN signaling is a central IECautonomous antiviral defense pathway against RV (26, 62).
These murine models of RV infection have been highly
concordant with recent reports examining the interactions
between human IECs and HRV (19, 54).
Transcriptional responses of HRV-infected HIE cultures
obtained from different patients reveal that the pathways most
dramatically modulated by HRV involve IFN signaling.
Speciﬁcally, of the 63 genes upregulated during HRV infection
of HIEs, 55 are ISGs and 3 are type III IFNs, suggesting a
predominantly type III IFN-driven signature (Figure 2B) (19). A
decrease in ISGs upon treatment of HRV-infected HIEs with
type III IFN receptor-blocking antibody conﬁrms this ISG
response is type III IFN-mediated. Collectively, these analyses
establish that endogenous type III IFN signaling is largely
regulating ISG induction in response to RV infection in
HIEs (19).
Other investigations have revealed similar ﬁndings, as a
signiﬁcant upregulation of ISGs, most notably IFIT2 and
IFITM3, was observed during a transcriptomic analysis of RVexposed biliary fetal liver organoids (52), and infection of HIEs
with RV strain SA11 similarly induces a swath of ISGs in murine
and human organoids, including IRF1, IRF7, IRF9, and IFITM1
(54). ISG expression with anti-RV activity is observed in HIEs

Human rotavirus (HRV) and mammalian reovirus (MRV)
are non-enveloped double-stranded RNA viruses in the
Reoviridae family. HRV is the leading cause of mortality
related to diarrhea in children younger than 5 years of age
especially in low- and middle-income countries (1, 49).
Advances in the understanding of HRV infection and
pathogenesis and the development of oral RV vaccines have
dramatically reduced HRV-associated severe gastroenteritis and
mortality. Though clinical signs are rare after respiratory or
gastrointestinal infection with MRV, infection has been linked to
the triggering of immune responses to dietary gluten that
underlie celiac disease (49–51). Despite the known
gastrointestinal pathology associated with HRV and MRV
infections, there remain no approved therapeutics against
these pathogens, which continue to remain a public health
burden in global regions without safe access to water and
sanitation (1, 49).

HIE susceptibility to RV infection
The modulation of host immune responses to RV infection
remains an important area of focus in RV antiviral discovery. RV
has evolved numerous mechanisms to evade host immune
responses via antagonism of IFN signaling (52). Thus, the
development of effective therapeutics may hinge on targeting
cellular responses that could override these viral evasion
strategies. The use of 3D HIEs has proven to be a useful
model of RV-host interactions, as they are highly permissive
to HRVs, such as the Rotarix RV1 G1P[8] vaccine and Ito G3P
[8] strains, and recapitulate numerous aspects of HRV infection
such as tropism for enterocytes and enteroendocrine cells ex vivo
(53). HIE morphology also changes following HRV infection,
with an increased number of detached cells (53). Additionally,
both human patient-derived HIEs and murine intestinal
enteroids can be inoculated with the rhesus RV SA11
laboratory strain to explore differences in both the speciesspeciﬁc and human interindividual responses to RV infection
(54). The study of the heterogeneous responses to infection of
HIEs from different donors with different strains of HRV has
important potential for identifying both viral and host factors
that restrict RV activity. Collectively, the susceptibility of HIEs to
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HAstV, including non-classic HAstV-MLB (Melbourne)
(MLB1-3) and HAstV-VA/HMO (Virginia/Human-MinkOvine-like) (VA1-5) remain poorly deﬁned (70). The
understanding of HAstV pathogenesis has evolved with the
development of relevant models for replication in cell lines
(21, 70–72). Additionally, the recent identiﬁcation of murine
astrovirus (muAstV) as an endemic virus in mouse facilities (71)
and HIE culturing methods for HAstVs have resulted in
important advancements in HAstV pathobiology (21, 28, 73).
MuAstV preferentially replicates in the small intestine and
chronically infects immunocompromised mice (21, 22, 71),
and some strains have been found to induce chronic antiviral
signaling via type III IFN, supporting important interactions
between AstVs and IFN signaling.

treated with type I IFN (54), and a hyperactive type III IFN
response secondary to genetic alterations causes RV resistance in
both HIEs and mice (63, 64). Interestingly, despite the important
role of endogenous type III IFN signaling in the transcriptional
response to RV infection, this pathway does not restrict HRV
replication in HIEs. In contrast, exogenous treatment with type I
or III IFNs does restrict HRV, with type I IFN demonstrating
greater efﬁcacy (Figure 2B) (19). Importantly, variability in HRV
replication and sensitivity to IFN in HIEs have been observed
between HRVs derived from different patients, with distinct
antiviral activity of IFN-a and ribavirin observed for different
viruses (54). Collectively, these ﬁndings suggest that HIEs can
serve as a powerful model to both explore IFN-HRV interactions
and to anticipate the sensitivity of individual HRV strains
to treatment.

HAstV can be cultivated in enteroids
Mammalian reovirus-infected HIEs have
similar responsiveness to IFNs

While some HAstV strains can replicate in immortalized cell
lines, such as Caco-2, HT-29, and MA104 cells, there is not an
existing conventional mammalian cell culture system for the
non-classical HAstV-MLB and HAstV-VA/HMO strains (72).
HIE model systems have been more recently leveraged as a
physiologically relevant model for HAstV infection. Notably, 2D
monolayer HIEs are susceptible to HAstV infection, with
analyses of replication kinetics indicating that maximal viral
titers occur by three days post-infection. VA1-infected HIEs
reveal a multicellular viral tropism for human IEC types
including progenitor cells, absorptive enterocytes, and goblet
cells, consistent with observations in HAstV1-infected 2D HIEs
(11, 73). Enteroid cultures have also provided insights into AstV
infectivity in the gastrointestinal tract. 3D HIEs inoculated with
classical human strain HAstV1 demonstrate up to a 30-fold
increase in viral genomes by 24 hours post-infection, suggesting
that HAstVs may infect via apical or basolateral entry (21). In
contrast, muAstV can only be cultivated in 2D but not 3D
murine enteroids, suggesting the importance of apical viral entry
for muAstV (21). Collectively, these ex vivo approaches reveal
that HAstV strains display robust viral replication in HIE model
systems and suggest HIEs as a helpful model to further
investigate immune responses and regulation of infection by
IECs during HAstV infection.

Similar ﬁndings have been observed in organoids inoculated
with MRV. Apical/basolateral-speciﬁc immune responses have
been investigated, wherein for both 2D Transwell cultures and
micro-injected 3D organoids, it was determined that basolateral
infection with MRV resulted in stronger type III IFN production
(65). MRV infection of colonoids is associated with an
upregulation of type III and, to a lesser extent, type I IFN, as
well as an upregulation of ISGs Viperin and IFIT1 (66). Further,
exogenous treatment with type I or III IFN results in a signiﬁcant
reduction in the number of MRV-infected cells and higher
expression of ISGs in a dose-dependent manner (66). Overall,
results stemming from HIE modeling of MRV infection support
IFNs as effective at limiting a spectrum of viruses in the
Reoviridae family.
These results collectively support the value of HIEs as
physiologically relevant models that can recapitulate ﬁndings
observed in murine models of infection, similarly revealing IFNISG signaling as a dominant pathway induced by HRV and
MRV infection. Further, studies thus far support the promise of
HIEs toward a personalized medicine-based approach to the
development of anti-HRV therapeutics.

Human astrovirus
HAstV-infected HIEs show IFN responses
Human astroviruses (HAstV) are single-stranded RNA
viruses in the family Astroviridae that contribute signiﬁcantly
to the global burden of pediatric acute gastroenteritis (67–69).
Speciﬁcally, HAstV serotypes 1-8 are important causes of
gastroenteritis in pediatric and elderly patients as well as in
immunocompromised populations. The epidemiologic
characteristics of other more recently-discovered groups of
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AstV infection of enteroids has been shown to induce
antiviral IFN responses that may be strain- or species-speciﬁc.
HAstV1-infected 3D HIEs exhibit a signiﬁcant transcriptional
increases in type I and III IFNs and multiple ISGs, including
IFNB1, IFNL2/3, OAS2, MX1, and IFI44 (11, 21, 28). Similarly,
the majority of upregulated genes in HIEs at 24 hours post-
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infection with VA1 are involved in type I and III IFN signaling,
including IFNL1, IFNA1, and IFNB1, and numerous
downstream ISGs (73) (Figure 2C). While a strong antiviral
IFN response occurs in VA1-infected HIEs, this response is not
observed in VA1-infected Caco-2 cells, emphasizing potential
differences in innate immune signaling between immortalized
cells and HIEs after viral infection (73). In contrast, murine 2D
air-liquid interface cultures exclusively exhibit type III IFN and
ISG induction after muAstV infection, most likely originating
from goblet cells and enterocytes (21). Single cell RNAsequencing of HIEs infected with HAstV1 infection indicates
cell-type-speciﬁc transcriptional patterns of ISG expression,
present both prior to infection and differentially induced
following infection, emphasizing the value of analyzing viral
infection in the heterogeneous mixture of cell types that make up
HIEs (11).
HAstV exhibits sensitivity to both exogenous and
endogenous IFN signaling. With regard to endogenous IFNs,
treatment of HIEs with ruxolitinib to block STAT1 activation
and inhibit ISG induction facilitates replication of HAstV1,
VA1, and MLB1 as well as a clinical HAstV isolate, though
notably with differences in response across distinct HIE lines,
indicating variation among donor genotypes in HAstVmediated IFN regulation (Figure 2C) (73). Collectively, these
studies have begun to address gaps in our understanding of host
responses to AstV infection, but raise important questions
related to the individual variation in immune response
requiring further investigation in the translational approach to
understanding HAstV-impact on the host immune landscape.

HIEs are susceptible to HAdV infection
and restricted by IFNs
HAdVs have proven challenging to cultivate in cell lines due
to their fastidious nature and undetermined cytopathic effect
(78). Immortalized cell lines including a 293 line expressing
cytomegalovirus IE1 protein, A549 and Hep2 cells have been
used to cultivate HAdVs including from stool isolates (78–80),
but these systems are imperfect models for interactions between
HAdV and the gastrointestinal tract. HAdV is detectable along
the entire intestinal tract in biopsy samples, with the highest
levels in the terminal ileum (81). In situ hybridization for HAdV
in intestinal biopsy specimens from patients with HAdV
reactivation suggests that HAdV may replicate in mucosal
lymphoid cells as well as epithelial cells (81). Consistent with
this reported tropism for IECs, enteric and nonenteric HAdVs,
including prototype HAdV strains and clinical HAdV isolates,
have been shown to productively replicate in HIEs, with
undifferentiated HIEs supporting replication of HAdV-5p,
HAdV-16p, and HAdV-41p, and differentiated HIEs
supporting replication of HAdV-41p (80). HIE modeling of
HAdV infection has also revealed a tropism of HAdV-5p, but
not HAdV-41p, for goblet cells (80). Further, undifferentiated
HIEs inoculated with four different HAdV-41 clinical isolates
also support viral replication (80). Though limited studies have
been conducted in HIEs to study IFN regulation, ﬁndings to date
indicate that IFN treatment of HIEs can attenuate HAdV
replication (Figure 2D) (80). No induction of ISGs occurred in
HIEs in the absence of IFN pretreatment, though monolayers
derived from differentiated HIEs pretreated with IFN-b or IFNl3 demonstrate attenuated replication of both HAdV-5p and
HAdV-41p (80). Therefore, while HIE modeling of HAdV
infection is still in the early stages, it clearly represents a new
opportunity to deﬁne targets and develop immunotherapeutics
against this pathogen.

Human adenovirus
Human adenoviruses (HAdV), double-stranded DNA
viruses in the Adenoviridae family, display a broad tissue and
organ tropism, causing acute gastroenteritis as well as
respiratory infections, conjunctivitis, and cystitis (74). Children
and immunocompromised individuals are at risk of developing
serious and prolonged complications from HAdV infection, with
HAdV accounting for more than 10% of hospitalizations for
severe childhood gastroenteritis (75). In patients with HAdV
viremia, particularly allogenic stem cell transplant recipients,
HAdV can be detected in stool samples even prior to detection in
the peripheral blood (76), with invasive HAdV infections often
occurring secondary to viral reactivation (74). HAdV-F
serotypes (HAdV-40 and HAdV-41) have been established as
the most common agents of pediatric gastroenteritis, with nontype 40/41 adenoviruses such as species B, type 3 (B/3), C/2, and
A/31 types also commonly detected in HAdV gastroenteritis
(77). As for other viral causes of gastroenteritis, there remains a
lack of effective antiviral therapeutics and an unmet need to
better characterize the mechanisms of HAdV infection in
the intestine.
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Emerging HIE models of enteric and
non-enteric viruses
Evolving methods for human sapovirus
cell culture
Although HIE models have been established for many
enteric viruses, robust HIE systems are not yet available for
some, such as human sapovirus (HuSaV). HuSaV, a genus in the
Caliciviridae family with HNoV, is a major cause of
gastroenteritis in all age groups with children under age ﬁve
experiencing the highest burden of disease (82, 83). HuSaV is the
third greatest cause of diarrhea of all enteric pathogens in
children under 12 months, and the second-highest attributable
cause among children ages 12-24 months (82, 83). Molecular
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JAK1/2 signaling inhibitor ruxolitinib, which limits ISG
induction by EV71 and permits enhanced viral replication
(89). Intriguingly, treatment of HIEs with recombinant type I
and III IFNs restricts EV replication in a virus-speciﬁc manner,
with type I IFN most effective at limiting E11 and type III IFNs
preferentially restricting EV71 (89). In sum, studies to date
suggest that HIEs are a powerful model to look at virusspeciﬁc interactions of EVs with the host epithelium, and
support that IFNs can serve as critical regulators of these
pathogens in intestinal tissues.

epidemiologic analyses have identiﬁed 19 genogroups of HuSaV,
with GI and GII among the most commonly detected (84).
Currently, among SaV genogroups, efﬁcient cell culture systems
have been established for the porcine SaV Cowden (GIII) strain
using porcine kidney cell lines but no animal model is available
(83, 85). However, propagation of HuSaV in cell culture has been
lacking. HIEs and immortalized cell lines inoculated with
HuSaV have been used for quantiﬁcation of RNA levels over
time, but no substantial HuSaV replication was observed among
these cell lines, even when co-cultured with bacteria (85). More
recently, bile acids, particularly sodium glycocholate and sodium
glycochenodeoxycholate, have been reported as necessary for
efﬁcient GI.1 and GII.3 HuSaV growth in human duodenal cell
line HuTu80 (86). Detection of double-stranded RNA, structural
and nonstructural viral proteins, and viral particles support
HuSaV replication in the presence of bile acids in these
immortalized cells (86). Future investigations reﬁning HIE
cultivation methods using relevant co-factors such as bile acids
will be needed to further explore the host cell factors and innate
immune responses associated with HuSaV infection.

Exploration of intestinal infection by
SARS-CoV-2 using HIEs
HIE modeling has also proven useful in the investigation of
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),
the cause of coronavirus disease 2019 (COVID-19) and the
current global pandemic (90). SARS-CoV-2, a single-stranded
positive-sense enveloped RNA virus of the Coronaviridae family,
is best known for causing an inﬂuenza-like illness with
respiratory transmission (90), but substantial clinical evidence
supports that SARS-CoV-2 can also replicate in the
gastrointestinal tract, causing symptoms such as diarrhea and
vomiting as well as prolonged fecal shedding of viral genomes
even after virus is undetectable in oropharyngeal swabs (91, 92).
Differentiated HIEs can be readily infected by SARS-CoV-2 and
support robust viral replication (93–96). HIE modeling has
revealed enterocytes and proliferating cells as the primary
target cell types for SARS-CoV-2, with ﬁndings suggesting that
the virus is primarily secreted from the apical surface of
enterocytes, as supernatants of lysed HIEs contain higher
levels of SARS-CoV-2 (93). Analysis of gene expression
changes indicate that SARS-CoV-2-infected HIEs exhibit
robust induction of type I and III IFNs as well as numerous
ISGs (93, 97, 98), and SARS-CoV-2 colonoids exhibit a
particularly dramatic upregulation of type III IFN (94). SARSCoV-2 replication in colonoids is additionally sensitive to type I
or III IFN treatment, with related studies in immortalized colon
carcinoma T84 cells suggesting that type III IFNs may yield
more effective antiviral control of SARS-CoV-2 (94, 99). As
SARS-CoV-2 is the third emerging highly pathogenic
coronavirus and remains a major global health threat, these
ﬁndings importantly suggest that HIEs and colonoids can
represent useful models for advancing insights into
coronavirus biology in the context of enteric infection.

HIE modeling of IFN responses during
human enterovirus infection
HIE modeling has also been implemented for investigation
of viruses that can infect via the gastrointestinal tract but are not
classical causes of acute gastroenteritis, such as human
enteroviruses. Human enteroviruses (EVs) are positivestranded RNA viruses belonging to the family Picornaviridae
and include coxsackieviruses, echoviruses, and poliovirus. These
viruses cause a broad spectrum of illnesses in humans targeting a
variety of tissues including both the airway and gastrointestinal
tracts, and can be spread via the fecal-oral route or respiratory
secretions (25). HIEs were recently found to be susceptible to
infection by diverse EVs including echovirus 11 (E11),
coxsackievirus B (CVB), and enterovirus 71 (EV71) (87–89).
While HIEs grown in Matrigel do not support robust replication
of EV-D68, infection of basal and apical compartments of HIEs
in Transwells supports high titer replication (25, 89). Contrary to
infection of immortalized Caco-2 cells, infection of HIEs
stimulates virus-speciﬁc antiviral and inﬂammatory signaling
pathways, with RNA sequencing analysis revealing that E11, but
not CVB, potently induces cytokines including type III IFNs,
chemokines, and ISGs in HIEs (87). EV-D68 infection of HIEs
does not induce detectable changes in any of the cytokines
tested, including IFNs, in contrast to infection of primary
human bronchial epithelial (HBE) cells, which results in the
induction of type III IFNs (25). In the context of apical infection,
type III IFNs and ISGs are robustly induced after EV71 infection
(87–89). The importance of induction of endogenous IFNs in
regulation of EV has been shown via treatment of HIEs with
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Conclusions and future directions
Though a critical role for IFNs in broadly regulating viral
replication and dissemination at mucosal surfaces has been well-
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established in murine models, many of the speciﬁc aspects of
IFN interactions with human enteric viruses have remained
obscure due to an absence of physiologically-relevant culture
systems. Here, we have focused on recent reports of IFNmediated immune responses to enteric viral infection using
emerging HIE systems. HIEs are powerful tools for
recapitulating the human intestinal epithelial interface, and
their use for the study of human enteric viruses has permitted
early interrogations of innate antiviral defenses, with
overlapping but distinct IFN pathways and genes elicited by
different viral stimuli. Why do some enteric viruses induce both
type I and III IFNs while others are speciﬁc for type III IFN
induction? What sensors and pathways govern the detection of
viruses by IECs to drive antiviral signaling? Further, HIEs
demonstrate donor-speciﬁc characteristics to these responses,
suggesting HIEs may recapitulate the range of potential human
responses. Further exploration of these host- and virus straindependent differences is thus highly warranted (28).
Consideration of the characteristics of the HIE systems
employed for the study of enteric virus responses will also be
important for future studies. While 2D and 3D HIE systems have
been leveraged, the emerging approach of apical-out or “insideout” enteroids may facilitate the study of host-virus responses, as
viral host entry predominantly occurs on the apical surface of
HIEs. Additionally, several limitations for HIEs as fully
representative models of the human gastrointestinal tract still
remain, including the absence of a microbiota and the lack of
immune cells that interact intimately with IECs. The ongoing
evolution of HIE platforms to incorporate these components will
permit deeper interrogation of the pathogenesis and the innate
immune responses to enteric viral infections. Finally, continued
exploration of the role of viral antagonists in regulating IFN
signaling during infection will be important. While some viruses
are sensitive to endogenous IFN regulation, others have already
evolved mechanisms to limit host control, and HIEs are likely to
be critical systems for exploring these distinctions. Overall,
further exploration of the interplay between viral and host
factors at the human intestinal epithelium using HIEs is likely
to be a key step in the development of antiviral therapies and

vaccines for vulnerable populations impacted by these highly
infectious viruses.
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